Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Total Non-Current Liabilities (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Total Non-Current Liabilities for 16 consecutive years, with $526.8 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 548.99% to $526.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $526.8 million through Dec 2025, up 548.99% year-over-year, with the annual reading at $526.8 million for FY2025, 548.99% up from the prior year.
  • Total Non-Current Liabilities hit $526.8 million in Q4 2025 for Ligand Pharmaceuticals, up from $506.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $526.8 million in Q4 2025 to a low of $57.7 million in Q3 2023.
  • Historically, Total Non-Current Liabilities has averaged $230.0 million across 5 years, with a median of $140.2 million in 2022.
  • Biggest five-year swings in Total Non-Current Liabilities: plummeted 72.85% in 2023 and later soared 548.99% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $446.9 million in 2021, then plummeted by 69.25% to $137.4 million in 2022, then crashed by 57.4% to $58.5 million in 2023, then soared by 38.65% to $81.2 million in 2024, then skyrocketed by 548.99% to $526.8 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for LGNDZ at $526.8 million in Q4 2025, $506.7 million in Q3 2025, and $105.7 million in Q2 2025.